Aderis Pharmaceuticals, Inc.
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Aderis Pharmaceuticals, Inc.
Ensho Joins Race To Develop An Oral Integrin Inhibitor For IBD
Ensho Therapeutics is raising series A cash to develop Phase II-ready NSHO-101 (EA1080), a third oral ɑ4β7 integrin inhibitor attempting to take on Takeda’s blockbuster injectable Entyvio.
Alnylam’s Amvuttra Market May See Tenfold Increase After Phase III Win
The company posted positive results from the HELIOS-B trial in patients with ATTR-CM, which represents a much larger population than the approved hATTR-PN indication.
Roche Adds Ascidian’s RNA-Writing To Its Neurology Push
A first big pharma partnership for Ascidian, headed up by ex-Biogen research head Michael Ehlers, as the Swiss firm expands its gene editing and neuroscience efforts.
BIO: Bayer Operational Model Benefits From Its Arm’s Length Biotechs
There is a lot of structural change going on at the German major but it is learning from the way its wholly owned subsidiaries such as AskBio and BlueRock are run.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice